phosphatidylcholine transfer proteinGenealiases: PC-TP · STARD2
Q-omics provides the consensus-scored PCTP profile across patient tissues and cancer cell-line models. PCTP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PCTP is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, PCTP RNA expression shows 18,710 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LUSC, and ACC as cancer lineages where PCTP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCTP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCTP survival associations across molecular data types. PCTP RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCTP RNA expression–survival associations across cancer types. High PCTP expression shows unfavorable associations in HNSC, UVM, KICH and KIRP, but favorable associations in KIRC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PCTP RNA expression.
This table summarizes PCTP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PCTP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCTP shows lower tumor expression in LUSC, CHOL and KICH and higher tumor expression in HNSC, KIRP and BLCA. The LUSC box plot shows higher PCTP RNA expression in normal versus tumor tissue (log2 FC = −0.778, t-test p < 0.001).
This table shows molecular features associated with PCTP in patient tissues and cancer cell lines. In patient samples, PCTP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCTP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
